Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V P Werth

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgarisD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|August 16, 2014
A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone aloneR P Hall, J Fairley, D Woodley, et al.
The British Journal of Dermatology|July 12, 2008
Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositisR Q Klein, C A Bangert, M Costner, et al.
The British Journal of Dermatology|August 18, 2017
Effect of long-term treatment with tumour necrosis factor-α inhibitors on single-dose ultraviolet-induced changes in human skinH J Kim, J L Langenhan, E S Robinson, et al.
Lupus|December 8, 2004
Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosusJ Albrecht, J A Berlin, I M Braverman, et al.
The British Journal of Dermatology|May 4, 2019
Developing classification criteria for skin-predominant dermatomyositis: the Delphi processJ S S Concha, S Pena, R G Gaffney, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
Arthritis and Rheumatism|March 4, 2008
The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatologyM S Krathen, J Dunham, E Gaines, et al.
Autoimmunity Reviews|January 13, 2011
Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practiceM Mosca, C Tani, M Aringer, et al.
The British Journal of Dermatology|January 23, 2016
Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigusC Boulard, S Duvert Lehembre, C Picard-Dahan, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgarisD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|August 16, 2014
A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone aloneR P Hall, J Fairley, D Woodley, et al.
The British Journal of Dermatology|July 12, 2008
Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositisR Q Klein, C A Bangert, M Costner, et al.
The British Journal of Dermatology|August 18, 2017
Effect of long-term treatment with tumour necrosis factor-α inhibitors on single-dose ultraviolet-induced changes in human skinH J Kim, J L Langenhan, E S Robinson, et al.
Lupus|December 8, 2004
Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosusJ Albrecht, J A Berlin, I M Braverman, et al.
The British Journal of Dermatology|May 4, 2019
Developing classification criteria for skin-predominant dermatomyositis: the Delphi processJ S S Concha, S Pena, R G Gaffney, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
Arthritis and Rheumatism|March 4, 2008
The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatologyM S Krathen, J Dunham, E Gaines, et al.
Autoimmunity Reviews|January 13, 2011
Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practiceM Mosca, C Tani, M Aringer, et al.
The British Journal of Dermatology|January 23, 2016
Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigusC Boulard, S Duvert Lehembre, C Picard-Dahan, et al.
Pageof 10